Jamp-Telmisartan tablet: Overweight & Underweight tablets
Brand(s)
Last updated
Summary
Product
Jamp-Telmisartan 40 mg & 80 mg tablet
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
Jamp |
Jamp-Telmisartan 40 mg tablet |
DIN 02386755 |
Tablet |
Telmisartan 40 mg |
EG22TMV005, EG22TMV006, EG22TMV007, EG23TMT001, EG23TMT002, EG23TMT003, EG23TMV001, EG23TMV002, EG23TMV003, EG24TMV002 |
Jamp |
Jamp-Telmisartan 80 mg tablet |
DIN 02386763 |
Tablet |
Telmisartan 80 mg |
EG22TMX007, EG22TMX009, EG22TMU002, EG23TMU001, EG23TMU002, EG23TMX001, EG23TMX002 |
Issue
Affected lots may contain overweight or underweight tablets.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
JAMP Pharma Corporation.
1310 Nobel,
Boucherville, QC, J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-76020
Get notified
Receive notifications for new and updated recalls and alerts by category.